SCHEMBL7226579

SCHEMBL7226579

CC(=O)O[C@H]1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2CCC4C)CC1C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.70
KDM4E B2RXH2 10/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CYP1A2 P05177 1/20 0.49
ALDH1A1 P00352 7/20 0.47
HPGD P15428 7/20 0.47
HSD17B10 Q99714 5/20 0.47
KCNH2 Q12809 4/20 0.47
POLB P06746 3/20 0.47
OPRM1 P35372 2/20 0.47
PRKD3 O94806 1/20 0.47
ALOX15 P16050 1/20 0.47
CLK2 P49760 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
OPRD1 P41143 1/20 0.47
ALB P02768 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7234796 0.91 LMNA (0.73) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7234417 0.91 LMNA (0.67) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7227118 0.90 LMNA (0.66) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7225956 0.89 LMNA (0.69) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL3971386 0.88 LMNA (0.78) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL10996219 0.88 LMNA (0.78) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL4369351 0.87 LMNA (0.79) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7762057 0.87 LMNA (0.79) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL4369898 0.87 LMNA (0.79) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1
SCHEMBL4379656 0.87 LMNA (0.79) LMNAKDM4ESMN1; SMN2CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608078-B2 Gramnegative bacteria WOCKHARDT LIMITED (IN) 2003-08-19 US claimed
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment WOCKHARDT RESEARCH CENTER 2002-11-07 US claimed
US-6608078-B2 Gramnegative bacteria WOCKHARDT LIMITED (IN) 2003-08-19 US disclosed
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment WOCKHARDT RESEARCH CENTER 2002-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment ALPI, POLR1C, POLI LMNA 1788/4885KDM4E 2308/4885SMN1; SMN2 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.